

# Edward Gane

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9137767/publications.pdf>

Version: 2024-02-01

87  
papers

12,512  
citations

76294

40  
h-index

66879

78  
g-index

87  
all docs

87  
docs citations

87  
times ranked

8852  
citing authors

#	ARTICLE	IF	CITATIONS
1	The roadmap towards cure of chronic hepatitis B virus infection. Journal of the Royal Society of New Zealand, 2022, 52, 129-148.	1.0	2
2	Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study. Liver International, 2022, 42, 1278-1286.	1.9	3
3	Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Alimentary Pharmacology and Therapeutics, 2022, 56, 510-518.	1.9	6
4	Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2021, 39, TPS2680-TPS2680.	0.8	3
5	IDDF2021-ABS-0077...Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment. , 2021, , .		2
6	Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. Journal of Viral Hepatitis, 2021, 28, 1635-1642.	1.0	12
7	Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clinical Infectious Diseases, 2020, 70, 1900-1906.	2.9	61
8	Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. Hepatology, 2020, 72, 7-18.	3.6	24
9	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clinical Infectious Diseases, 2020, 71, e115-e124.	2.9	53
10	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical Microbiology Reviews, 2020, 33, .	5.7	239
11	Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatology Research, 2020, 50, 1109-1117.	1.8	6
12	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver International, 2020, 40, 2385-2393.	1.9	5
13	Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease. JCI Insight, 2020, 5, .	2.3	37
14	The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, e81-e89.	0.9	0
15	Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge. ACG Case Reports Journal, 2020, 7, e00499.	0.2	2
16	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	6.1	195
17	Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand. Journal of Viral Hepatitis, 2019, 26, 1372-1376.	1.0	0
18	Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. Journal of Hepatology, 2019, 71, 900-907.	1.8	229

#	ARTICLE	IF	CITATIONS
19	LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e130.	1.8	23
20	FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients. <i>Journal of Hepatology</i> , 2019, 70, e491.	1.8	15
21	Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. <i>Internal Medicine Journal</i> , 2019, 49, 1405-1411.	0.5	10
22	Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. <i>Journal of Gastroenterology</i> , 2019, 54, 752-761.	2.3	17
23	Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 296-304.	3.7	23
24	IDDF2019-ABS-0136...Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis. , 2019, , .		1
25	Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. <i>Liver Transplantation</i> , 2019, 25, 25-34.	1.3	35
26	Glecaprevir/Pibrentasvir in patients with chronic <sc>HCV</sc> genotype 3 infection: An integrated phase 2/3 analysis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 337-349.	1.0	32
27	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 257-266.	0.4	15
28	Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 217-226.	0.8	8
29	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 45-51.	3.7	48
30	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018, 68, 1298-1307.	3.6	158
31	Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients. <i>Liver Transplantation</i> , 2018, 24, 1031-1039.	1.3	38
32	Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018, 378, 354-369.	13.9	361
33	Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3. <i>Clinical Therapeutics</i> , 2018, 40, 704-718.e6.	1.1	5
34	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1 patients without cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 293-300.	1.8	127
35	Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. <i>Journal of Hepatology</i> , 2018, 68, 814-826.	1.8	35
36	IDDF2018-ABS-0108...Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB). , 2018, , .		2

#	ARTICLE	IF	CITATIONS
37	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	1.6	58
38	Intention-to-treat analysis of liver transplantation, resection and thermal ablation for hepatocellular carcinoma in a single centre. <i>Hpb</i> , 2018, 20, 966-976.	0.1	4
39	Hepatic venous outflow obstruction in piggyback liver transplantation: single centre experience. <i>ANZ Journal of Surgery</i> , 2017, 87, 182-185.	0.3	10
40	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	3.7	45
41	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1 without cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 263-271.	1.8	261
42	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. <i>New England Journal of Medicine</i> , 2017, 377, 1448-1455.	13.9	348
43	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. <i>Journal of Hepatology</i> , 2017, 66, 11-18.	1.8	52
44	Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx154.	0.4	14
45	Reply. <i>Gastroenterology</i> , 2017, 153, 867.	0.6	0
46	Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction. <i>Case Reports in Medicine</i> , 2017, 2017, 1-5.	0.3	4
47	A phase 2 study of galunisertib (TGF- $\beta$ 1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4097-4097.	0.8	5
48	Sofosbuvir/Velpatasvir Plus GS-9857 (100 Milligrams) for 6, 8, or 12 Weeks in Genotype 1-6 Hepatitis C Virus (HCV)-Infected Patients: An Integrated Analysis of Safety and Efficacy From Two Phase 2 Studies. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
49	HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes. <i>Hepatology International</i> , 2016, 10, 829-837.	1.9	18
50	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw507.	2.9	58
51	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE II study. <i>Hepatology</i> , 2016, 64, 1911-1921.	3.6	50
52	High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. <i>Gastroenterology</i> , 2016, 151, 651-659.e1.	0.6	90
53	A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF- $\beta$ 2) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4070-4070.	0.8	19
54	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	1.8	31

#	ARTICLE	IF	CITATIONS
55	Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1457-1464.	1.1	249
56	Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015, 60, 260-268.	1.1	29
57	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , 2015, 62, 79-86.	3.6	232
58	Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. <i>Hepatology International</i> , 2015, 9, 243-250.	1.9	52
59	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	0.6	317
60	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	1.8	59
61	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. <i>Gastroenterology</i> , 2015, 148, 100-107.e1.	0.6	307
62	Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study. <i>Gut</i> , 2015, 64, 966-972.	6.1	28
63	Infrequent Development of Resistance in Genotype 1 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 1666-1674.	2.9	199
64	Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B. <i>Gastroenterology</i> , 2014, 146, 980-988.e1.	0.6	145
65	Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1349-1359.e13.	2.4	87
66	Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). <i>Journal of Hepatology</i> , 2014, 60, 741-747.	1.8	88
67	No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2106-2112.e1.	2.4	37
68	Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 61-74.	0.5	10
69	Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. <i>Lancet</i> , 2013, 381, 468-475.	6.3	1,476
70	Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. <i>Gastroenterology</i> , 2011, 140, 132-143.	0.6	419
71	Future hepatitis C virus treatment: interferon-sparing combinations. <i>Liver International</i> , 2011, 31, 62-67.	1.9	36
72	Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2727-2734.	1.1	83

#	ARTICLE	IF	CITATIONS
73	Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 51, 11-20.	1.8	185
74	2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2009, 136, 486-495.	0.6	527
75	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. <i>Hepatology International</i> , 2008, 2, 263-283.	1.9	832
76	Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. <i>Vaccine</i> , 2007, 25, 8585-8597.	1.7	160
77	Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2007, 357, 2576-2588.	13.9	735
78	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. <i>Liver International</i> , 2005, 25, 472-489.	1.9	313
79	Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2005, 352, 2682-2695.	13.9	1,465
80	Treatment of chronic hepatitis C in patients with renal disease. <i>Medical Journal of Malaysia</i> , 2005, 60 Suppl B, 72-6.	0.2	0
81	Liver transplantation in chronic hepatitis B. <i>Medical Journal of Malaysia</i> , 2005, 60 Suppl B, 88-9.	0.2	0
82	Renal transplantation in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S99-S102.	1.4	4
83	Resolution of alcoholic neuropathy following liver transplantation. <i>Liver Transplantation</i> , 2004, 10, 1545-1548.	1.3	16
84	The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. <i>Liver Transplantation</i> , 2003, 9, S28-S34.	1.3	198
85	Management of chronic viral hepatitis before and after renal transplantation. <i>Transplantation</i> , 2002, 74, 427-437.	0.5	150
86	Peginterferon Alfa-2a in Patients with Chronic Hepatitis C. <i>New England Journal of Medicine</i> , 2000, 343, 1666-1672.	13.9	1,173
87	Pre- and post-transplant treatment of hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E187-E193.	1.4	2